SMARCA4 and non-small cell lung carcinoma: To identify targetable gene products related to SMARCA4-inactivating mutations, we applied a high-throughput, cell-based, one-well/one-gene screening platform with a genome-wide library of chemically synthesized small interfering RNAs (siRNAs) looking for essential genes in SMARCA4-null NSCLC cells that encoded cellular machinery linked to a known drug target.